JPRN-UMIN000005426已完成未知
Crossover comparative study of latanoprost/timolol fixed combination with combined therapy comprised of latanoprost and timolol - Xalacom crossover study
Department of Ophthalmology, Gifu University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2011年4月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Contraindication for latanoprost or timolol MD worse than or equal to -25dB (HFA 30-2) BCVA less than 0.5 Refractive error greater than or equal to +9.0D, or less than -9.0D Goldmann applanation tomometry or disc evaluation difficult or impossible History of intraocular surgery or laser Other ocular diseases which may affect the results
研究者
相似试验
已完成
不适用
Comparison of latanoprost and timolol in the treatment for exfoliation glaucoma: A randomized controlled trial.JPRN-C000000425Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences60
已完成
不适用
Comparison of travoprost and latanoprost plus timolol fixed combinations in open-angle glaucoma and ocular hypertension patients previously treated with dorzolamide plus timolol fixed combination.primary open angle glaucoma, normal tension glaucoma and ocular hypertension patientsJPRN-UMIN000005974Department of Ophthalmology, National Defense Medical College70
已完成
不适用
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual AcuityOAG - Open-Angle GlaucomaOHT - Ocular HypertensionNCT03931317University of California, San Diego70
已完成
不适用
Comparison of tafluprost and latanoprost on progression of visual field loss in primary open angle glaucoma: prospective, randomized, open, multi-center study.GlaucomaJPRN-UMIN000004093Department of Ophthalmology, Akita Univ. School of Medicine120
已完成
3 期
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With GlaucomaGlaucoma, Open-AngleOcular HypertensionNCT00159653Pfizer's Upjohn has merged with Mylan to form Viatris Inc.500